ALT News & Events

Altimmune announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple cardiometabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis. The findings demonstrated reductions in triglycerides and total cholesterol, along with improvements in weight, waist circumference and blood pressure, highlighting the broad impact of pemvidutide on key drivers of MASH. The data were presented for the first time at the European Association for the Study of the Liver Congress 2026 in Barcelona, Spain. Highlights of the 48-week data presented at EASL 2026 include: Pemvidutide 1.8 mg treatment resulted in significant reductions in serum lipid levels among patients with elevated baseline values versus placebo, including: Triglycerides reductions of -23.7%; Total cholesterol reductions of -15.4%. In addition to lipids, pemvidutide 1.8 mg treatment resulted in significant improvements in other metabolic risk factors versus placebo: Weight loss of 7.5%, continuing throughout treatment with no plateauing; Reductions in body mass index of -3.0 kg/m2; Reductions in waist circumference of -5.3 cm; Improvements in systolic blood pressure of -4.0 mmHg and diastolic blood pressure of -2.2 mmHg. Results also showed that the safety profile of pemvidutide was maintained at 48 weeks, and the tolerability profile was generally favorable without dose titration. Approximately 1% of total patients receiving pemvidutide discontinued treatment due to adverse events. The majority of AEs were mild to moderate, and no imbalances in cardiac AEs were observed with pemvidutide versus placebo. Most gastrointestinal AEs were mild to moderate in severity and predominantly occurred within the first 8 weeks. Previously reported IMPACT Phase 2b trial results showed the proportion of patients achieving both a greater than or equal to0.5 reduction in Enhanced Liver Fibrosis and a greater than or equal to30% reduction in Liver Stiffness Measurement at week 48 was 3.2% with placebo, compared with 27.8% for pemvidutide 1.2 mg and 32.4% for pemvidutide 1.8 mg.

"We continue to make significant progress across multiple fronts, as we enter a new phase for Altimmune," said Jerry Durso, president and CEO of Altimmune. "As a result of the recent successful financing with top-tier biotech investors, we now have a strong cash position that enables us to focus on execution and delivering on our goal of bringing pemvidutide to patients with serious liver diseases and create long-term value for our shareholders. Looking ahead, we have several important milestones this year, including the initiation of the PERFORMA Phase 3 MASH trial, topline data from the RECLAIM Phase 2 AUD trial, and enrollment completion in the RESTORE Phase 2 ALD trial."